Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2016 · 10-Q
Revenue$508.70M$508.70M+8.2% vs Q3 2015 Net Income$17.10M$17.10M−1.7% vs Q3 2015 EPS Diluted$0.58$0.58−1.7% vs Q3 2015 Gross Profit$279,500,000+6.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$51,607,000−37.3% Free Cash Flowderived$12,149,000−78.9% Margins · derivedGross margin54.9%−1.1 pt vs Q3 2015
Operating margin4.5%−2.5 pt vs Q3 2015
Net margin3.4%−0.3 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 2, 2016 · 33 d after period end